Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches

Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches

RELEASE DATE
22-Feb-2013
REGION
Global
Research Code: 9837-00-55-00-00
SKU: LS00066-GL-MR_16907
AvailableYesPDF Download
$1,500.00
In stock
SKU
LS00066-GL-MR_16907
$1,500.00
DownloadLink
ENQUIRE NOW

Description

This research service provides an introduction to systemic lupus erythematosus (SLE), disease classification and diagnosis. Research in this report overviews the current status of SLE pipeline candidates with a focus on current Phase 3 candidates, detailed timelines with accrual rate and approval estimates for U.S. and European markets, ranking of the approval likeliness for current Phase 3 candidates, rationale for pivotal program design, Phase 2 data review, and KOL commentary. A pipeline assessment is provided for all active SLE candidates in development.

Table of Contents

Executive Summary

Methodology and Scope

Introduction

Competitive Landscape

Timeline Transparency

SLE Drug Trial Results

Product Dashboards

The Future of Treatment Decisions

Appendix

The Frost & Sullivan Story

Related Research
This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.
More Information
No Index Yes
Podcast No
WIP Number 9837-00-55-00-00
Is Prebook No